80096-64-6

Basic information

• Product Name: 6-HYDROXY-CHROMAN-4-ONE
• Synonyms: 6-hydroxy-2,3-dihydrochroMen-4-one
• CAS NO: 80096-64-6
• Molecular Formula: C₉H₈O₃
• Molecular Weight: 164.16
• Mol File: 80096-64-6.mol
• Article Data: 19

Chemical Properties

• Melting Point: 129-131 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• Boiling Point: 372.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.343±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.58±0.20(Predicted)
• CAS DataBase Reference: 6-HYDROXY-CHROMAN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-CHROMAN-4-ONE(80096-64-6)
• EPA Substance Registry System: 6-HYDROXY-CHROMAN-4-ONE(80096-64-6)

Safety Data

• Hazardous Substances Data: 80096-64-6(Hazardous Substances Data)

Usage

Description

6-Hydroxy-chroman-4-one is a chemical compound that belongs to the chroman family. It is characterized by the presence of a hydroxyl group at the 6th position and a carbonyl group at the 4th position in the chroman ring structure. 6-HYDROXY-CHROMAN-4-ONE has gained attention for its potential applications in various fields, particularly in the development of novel therapeutic agents.

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-chroman-4-one is used as a key intermediate in the synthesis of novel parasite transmission blocking antimalarials. These antimalarial agents are specifically designed to target male gametes, thereby disrupting the transmission of the malaria parasite and preventing the spread of the disease.
In the development of these novel antimalarials, 6-Hydroxy-chroman-4-one plays a crucial role in the chemical structure of the final product. Its unique properties and reactivity make it an ideal candidate for the creation of new drugs that can effectively combat malaria by targeting a previously unexplored aspect of the parasite's life cycle.
Furthermore, the use of 6-Hydroxy-chroman-4-one in the preparation of these antimalarials highlights its potential as a versatile building block in the pharmaceutical industry. Its ability to be modified and incorporated into various drug candidates makes it a valuable asset in the ongoing search for new and effective treatments for a wide range of diseases and conditions.

Upstream product

• 39223-40-0 3-(4-hydroxy-phenoxy)-propionic acid 
• 34985-50-7 4-methoxyphenyl 3-chloropropionate 
• 5802-17-5 6-methoxychroman-4-one 
• 625-36-5 2-chloropropionyl chloride 
• 108-46-3 recorcinol 
• 110704-60-4 5-fluoro-2-chloromethylbenzothiazole 
• 49660-57-3 6-bromochroman-4-one 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 1421659-47-3 2,3-dihydro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-1-benzopyran-4-one 
• 38445-24-8 6-hydroxy-4H-1-benzopyran-4-one 
• 90563-81-8 3-(4-hydroxyphenoxy)propionitrile 
• 123-31-9 hydroquinone 

Downstream Products

• 123094-61-1 6-benzyloxychroman-4-one 
• 158102-91-1 (3R,4R)-3-(5-Amino-2-methoxy-benzyl)-chroman-4,6-diol 
• 158102-86-4 3-(6-Benzyloxy-4-oxochroman-3-ylmethyl)-4-methoxybenzoic acid methyl ester 
• 158102-89-7 3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-benzoic acid 
• 251639-72-2 (3R,4R)-3-(5-Amino-2-methoxy-benzyl)-6-(7-chloro-quinolin-2-ylmethoxy)-chroman-4-ol 
• 251639-71-1 [3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-phenyl]-carbamic acid benzyl ester 
• 158102-93-3 CP-199,331 
• 251639-70-0 3-{6-benzyloxy-4-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyloxy]-chroman-3-ylmethyl}-4-methoxy-benzoic acid methyl ester 
• 1471989-14-6 6-tert-butyldiphenylsilyloxy-2,3-dihydro-4H-chromen-4-one 
• 176431-77-9 6-ethoxy-2,3-dihydro-4H-1-benzopyran-4-one 
• 1361926-67-1 6-[(4-fluorobenzyl)oxy]-4H-chromen-4-one 
• 1361926-63-7 6-[(4-chlorobenzyl)oxy]-4H-chromen-4-one 
• 4250-77-5 6-hydroxyflavanone 

Relevant articles and documents

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT

Described are polymerizable high energy light absorbing compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and X are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].